Related by context. All words. (Click for frequent words.) 77 hematologic toxicity 76 TEAEs 76 events AEs 76 treatment emergent adverse 76 pyrexia mucositis sepsis febrile 75 hematologic adverse 75 adverse reactions incidence 74 transaminase elevations 74 neutropenia dehydration dyspnea 74 non hematological toxicities 72 ALT flares 72 lopinavir r arm 72 Adverse events 72 peripheral sensory neuropathy 71 leucopenia 71 discontinuations due 71 lymphopenia 71 neutropenia thrombocytopenia 71 REYATAZ r arm 70 hematological adverse 70 adverse reactions irrespective 70 elevated ALT 70 FluCAM arm 70 neutropaenia 70 causality incidence 70 PREZISTA r arm 70 ocular adverse 70 hypophosphatemia 70 DLTs 69 leukopenia 69 haematologic 69 events SAEs 69 histologic subtype 69 oxycodone CR 69 sensory neuropathy 68 paresthesias 68 Baseline characteristics 68 incidence ≥ 68 hematologic toxicities 68 adverse reactions occurring 68 hypocalcemia 68 â ‰ ¥ 68 hypokalemia 68 febrile neutropenia 68 generalized edema 68 hypomagnesemia 68 arterial thromboembolic events 68 thrombocytopenia neutropenia 68 onset diabetes mellitus 68 treatment emergent AEs 68 hematological toxicities 67 x ULN 67 proctitis 67 QTc prolongation 67 Infusion Reactions Severe 67 severe NCI CTC 67 superficial edema 67 definite stent thrombosis 67 events TEAEs 67 adjunctive placebo 66 alanine aminotransferase 66 adverse reactions ≥ 66 non hematologic toxicities 66 extrapyramidal symptoms 66 certolizumab 66 MADRS score 66 mcg BID 66 TYSABRI treated 66 MACCE 66 neutropenia febrile neutropenia 66 Febrile neutropenia 66 EDSS scores 66 plus methotrexate 66 cerebrovascular events 66 thrombocytopenia 66 receiving XGEVA 66 severe exacerbations 66 hypoglycemic events 66 ACTEMRA TM 66 hematological toxicity 66 hyperbilirubinemia 66 thromboembolic events 66 dermatologic toxicities 66 Myelosuppression 65 headache nasopharyngitis 65 ALT elevations 65 intraocular inflammation 65 hypercalcemia 65 adverse reactions observed 65 anemia neutropenia 65 AEs 65 symptomatic VTE 65 dose limiting toxicities 65 LVEF 65 gastrointestinal toxicities 65 myelosuppression 65 peripheral edema 65 Postoperative complications 65 PREZISTA r 65 recurrent venous thromboembolism 65 adjunctive ABILIFY 65 pericardial effusion 65 HbA 1c levels 65 colorectal adenoma 65 recurrent VTE 65 cytogenetic response 65 linaclotide treated 65 SGPT 65 acneform rash 65 infusion reactions 65 fatigue asthenia 65 nasopharyngitis 65 baseline HbA1c 65 mcg QD 65 diarrhea nausea fatigue 65 β blockers 65 Index CDAI 65 receiving Vectibix monotherapy 65 morphometric vertebral fractures 65 neutropenic fever 65 alanine aminotransferase ALT 65 pericardial effusions 65 Stent thrombosis 65 4mg/kg 65 carotid stenosis 65 prolonged QT interval 65 corticosteroid therapy 64 hemorrhagic complications 64 EXJADE 64 esophagitis 64 arthralgia 64 elevated lipase 64 receiving VICTRELIS 64 primary generalized tonic 64 dapagliflozin plus 64 Hypotension 64 nonfatal MI 64 concomitant medications 64 HIV HCV coinfected 64 headache abdominal pain 64 moderate renal impairment 64 glycated hemoglobin levels 64 receiving VELCADE 64 Primary endpoints 64 PASI scores 64 Erythropoietic therapies may 64 relapsed MM 64 CIMZIA TM 64 aspartate aminotransferase AST 64 thromboembolic 64 #mg BID [001] 64 FOLPI 64 advanced adenomas 64 NYHA class 64 dysuria 64 tolvaptan 64 generalized seizures 64 Dose limiting toxicities 64 mucosal inflammation 64 aminotransferases 64 Serious ocular 64 myalgia arthralgia 64 chills fever headache 64 Treatment emergent adverse 64 concomitant AEDs 64 Hematologic toxicity 64 vWD 64 P = .# 64 HBeAg negative patients 64 advanced adenoma 64 achieved ACR# 63 ≥ 63 ECG abnormalities 63 cytopenias 63 intracranial hemorrhage ICH 63 patients receiving ERBITUX 63 thromboembolism 63 virologic failure 63 experienced hypomagnesemia 63 DAS# scores 63 Exacerbations 63 Neutropenia 63 recurrent DVT 63 HbA1c levels 63 TMP SMX 63 stomatitis 63 coronary stenosis 63 macroalbuminuria 63 headache nausea diarrhea 63 gastrointestinal perforation 63 APTIVUS r 63 ipsilateral stroke 63 affective psychosis 63 #mg BID [003] 63 nondiabetic patients 63 aspartate aminotransferase 63 dyslipidaemia 63 hydroxymethyl coenzyme 63 mg kg dose 63 fosamprenavir 63 metformin monotherapy 63 HbA 1c 63 diarrhea nausea vomiting 63 endophthalmitis 63 CIN3 63 nadroparin 63 renal insufficiency 63 SAEs 63 Toxicities 63 QTcF 63 subclinical hypothyroidism 63 solifenacin 63 Complication rates 63 hemoptysis 63 elevated LDH 63 INCB# [003] 63 enterocolitis 63 MCyR 63 limiting toxicity 63 Hypersensitivity reactions 63 syncopal 63 neutropenia anemia 63 desvenlafaxine succinate 63 nonvertebral fractures 63 cervical intraepithelial neoplasia 63 HBeAg seroconversion 63 serum creatinine levels 63 Flu Cy 63 p = NS 63 CCyR 63 reinfarction 63 clinically asymptomatic 63 mcg albinterferon alfa 2b 63 ertapenem 63 transaminases 63 pancytopenia 63 proximal DVT 63 CIMZIA ™ 62 severe hypersensitivity reactions 62 Hematologic 62 lipid lowering agents 62 nephrotoxicity 62 vesicoureteral reflux 62 mg TID 62 mg BID dose 62 generalized tonic clonic seizures 62 somatostatin analog 62 8mg/kg 62 del 5q MDS 62 ARB telmisartan 62 fulminant hepatitis 62 neuropsychiatric symptoms 62 toxicities 62 serum IGF 62 nontraumatic 62 neutrophil counts 62 unresectable HCC 62 Serious adverse reactions 62 virologic breakthrough 62 virological response 62 external genital lesions 62 anemia leukopenia 62 ATACAND 62 mcg mL 62 acromegalic patients 62 osteosarcomas 62 PSA nadir 62 dermatologic reactions 62 HBeAg positive 62 postoperative complication 62 mg BID 62 NYHA 62 lenalidomide dexamethasone 62 thyrotoxicosis 62 dizziness nausea diarrhea 62 Scale EDSS score 62 salmeterol HFA MDI 62 hyperphenylalaninemia HPA due 62 virologic response 62 mcg kg REBETOL 62 Dermatologic Toxicity Dermatologic toxicities 62 achieved statistical significance 62 biologic DMARD 62 clinically meaningful differences 62 Peripheral edema 62 evaluable subjects 62 nasopharyngitis headache 62 RLAI 62 subtrochanteric 62 oral prednisolone 62 COPD exacerbation 62 angiotensin converting enzyme inhibitors 62 neutropenia 62 CVD mortality 62 receiving INTRON 62 tumor histology 62 generalized epilepsy 62 jaw ONJ 62 virologic responses 62 cytogenetic responses 62 PGTC seizures 62 amenorrhoea 62 % CI #.#-#.# [003] 62 renal impairment 62 severe hypoglycemic 62 serum ALT 62 NNRTI resistance 62 AST ALT 62 comparator arm 62 hypoglycaemic episodes 62 PRADAXA #mg 62 discontinuations 62 Hypocalcemia 62 AGILECT R 62 Dermatologic toxicities 62 thromboembolic complications 62 proliferative diabetic retinopathy 62 CIMZIA TM certolizumab pegol 62 constipation nausea 62 pruritis 62 symptomatic pulmonary embolism 62 receiving ISENTRESS 62 tolterodine ER 62 macrovascular events 61 dyspareunia 61 caspofungin 61 placebo fluoxetine 61 oral allopurinol 61 ecchymosis 61 LEXIVA r 61 elevated bilirubin 61 OAB symptoms 61 daunorubicin 61 micafungin 61 neurologic complications 61 severe neutropenia 61 unfavorable cytogenetics 61 hallucinations dyskinesia 61 myopathy rhabdomyolysis 61 recurrent glioblastoma multiforme 61 hepatic enzymes 61 umol L 61 NNT = 61 CIN2 + 61 periprocedural 61 astrocytomas 61 arterial thromboembolic 61 oxygen desaturation 61 oral antidiabetic medication 61 Treatment discontinuations due 61 CC genotype 61 lymphocytosis 61 log# copies mL 61 teriflunomide 61 overt nephropathy 61 myocardial infarctions 61 Q2W 61 arterial occlusion 61 plus MTX 61 oral olanzapine 61 prednisone prednisolone plus 61 hepatic dysfunction 61 Renal impairment 61 NPH insulin 61 transaminase 61 microvascular complications 61 leiomyomas 61 overt hypothyroidism 61 benazepril 61 revascularization procedures 61 hyperglycaemia 61 % CI #.#-#.# [007] 61 CP CPPS 61 HBeAg negative 61 ventricular fibrillation VF 61 Thrombocytopenia 61 HBeAg positive patients 61 ALT elevation 61 asthenia 61 hypoglycemic episodes 61 VUR 61 serologically active patients 61 juvenile idiopathic arthritis JIA 61 TMC# r 61 dosage regimens 61 events MACE 61 hypercholesterolaemia 61 CTAP# Capsules 61 hepatorenal syndrome 61 Discontinuations due 61 macrovascular disease 61 left ventricular dysfunction 61 biochemical recurrence 61 LV dysfunction 61 RLS symptoms 61 Serious AEs 61 nicardipine 61 placebo p 61 anemia hemoglobin 61 NATRECOR ® 61 mg ustekinumab 61 hemorrhagic cystitis 61 placebo dexamethasone 61 #mg/day [001] 61 Secondary endpoints 61 BARACLUDE ® 61 NYHA functional class 61 HbA 1C 61 invasive aspergillosis 61 serum calcium 61 Pulmonary embolism 61 postoperative AF 61 biochemical relapse 61 aplastic anemia AA 61 plasma uric acid 61 hsCRP levels 61 NAbs 61 elevated creatinine 61 nonfatal stroke 61 hyperoxaluria 61 CrCl 61 TDF FTC 61 diarrhea headache nausea 61 CR nPR 61 venlafaxine XR 61 deep venous thromboses 61 Angioedema 61 rosuvastatin #mg 61 Viread Emtriva Sustiva 61 Asymptomatic 61 corticosteroid dose 61 neurologic symptoms 61 NMIBC 61 TNF antagonist 61 Psoriasis Area 61 hepatic adverse 61 essential thrombocythemia 61 serum leptin 61 univariate analysis 61 composite endpoint 61 virological failure 61 aortic insufficiency 61 titrated glipizide 61 oral levofloxacin 61 p = .# [002] 61 MMSE scores 61 aminotransferase levels 61 dyspnea 61 cTnT 61 infliximab monotherapy 61 gout flares 61 ICD shocks 61 ECOG PS 61 recurrent genital herpes 61 pheochromocytoma 61 psychiatric comorbidities 61 acute leukemias 61 endometrial hyperplasia 61 proliferative retinopathy 61 neoplasias 61 thrombocytopenia anemia 61 ACR# responses 61 hematological parameters 61 locoregional recurrence 61 Brief Psychiatric 61 hemodynamically significant 61 receiving golimumab 61 hypertensives 61 liver histology 61 undetectable HBV DNA 61 SCr 61 psoriatic arthritis PsA 61 mg/m2 dose 60 autoantibody positive 60 unstable angina pectoris 60 adrenal insufficiency 60 Crohn Disease Activity 60 typical antipsychotics 60 tipranavir r 60 lipid parameters 60 histologies 60 candidemia 60 Xeloda monotherapy 60 coronary stenoses 60 autonomic dysfunction 60 endometrial thickness 60 nadolol 60 highly emetogenic 60 tricuspid regurgitation 60 CHD mortality 60 intravenous bisphosphonates 60 euthymic patients 60 DOXIL 60 neurologic abnormalities 60 elevated liver enzymes 60 mL/min/#.# m 2 60 adalimumab 60 GOUT 60 eosinophilic asthma 60 unknown etiology 60 HAM D# scores 60 doxorubicin cyclophosphamide 60 polyarticular 60 comorbid conditions 60 salmeterol fluticasone 60 primidone 60 timepoints 60 apnea hypopnea 60 mg QD 60 conjunctival hyperemia 60 perioperative mortality 60 linear pharmacokinetics 60 prednisone prednisolone 60 reflux symptoms 60 MGUS 60 pulmonary exacerbations 60 posttreatment 60 tumor lysis syndrome 60 Perforomist Inhalation Solution 60 SVR# 60 chorioamnionitis 60 depressive symptomatology 60 MIC# [001] 60 anterior uveitis 60 serum calcium levels 60 intravascular hemolysis 60 ALVESCO 60 Peripheral neuropathy 60 HbA1C levels 60 pCR 60 spirometric 60 headache nausea fatigue 60 mucositis 60 cytogenetic abnormalities 60 System IPSS 60 recurrent UTI 60 thrombophlebitis 60 severe hypoglycemia 60 PREZISTA ritonavir 60 NATRECOR R 60 Hepatotoxicity 60 graft dysfunction 60 pyrexia 60 intravitreal injections 60 androgen excess 60 EDSS score 60 hyperprolactinemia 60 pathologic fractures 60 tapentadol ER 60 aldosterone antagonist 60 VIIBRYD 60 hip BMD 60 mild renal insufficiency 60 hamartomas 60 Recurrences 60 FluCAM 60 REYATAZ ritonavir 60 ‰ ¥ 60 hematologic 60 parkinsonian symptoms 60 % CI #.#-#.# [004] 60 intraventricular hemorrhage 60 BENICAR HCT 60 fasting plasma glucose 60 symptom exacerbation 60 atrioventricular block 60 SUVmax 60 budesonide pMDI 60 mediastinitis 60 Thrombolysis 60 idiopathic generalized epilepsy 60 Exclusion criteria 60 infarcts 60 radiographic findings 60 sternal wound infections 60 aortic regurgitation 60 lamotrigine 60 thrombocytosis 60 inhaled budesonide 60 T2 lesions 60 Discontinuations 60 odds ratios ORs 60 asthma exacerbation 60 thromboprophylaxis 60 onset atrial fibrillation 60 -#.# ± [002] 60 T1DM 60 SGRQ 60 mucocutaneous reactions 60 cholecystitis 60 Neovascular AMD 60 CYT# potent vascular disrupting 60 ABC/3TC 60 HER2 expression 60 urinary N telopeptide 60 serum phosphate levels 60 ritonavir boosted 60 juvenile idiopathic arthritis 60 relapsing remitting 60 hyperkalemia 60 exploratory endpoints 60 CI #.#-#.# [001] 60 malignancy HCM 60 pyridostigmine 60 atherogenic dyslipidemia 60 #mg/m# [001] 60 grade cervical intraepithelial 60 hyperreflexia 60 #q# deletion syndrome 60 % CI #.#-#.# [006] 60 elevated transaminases 60 ACR# response 60 epithelial tumors 60 aged ≥ 60 confidence interval #.#-#.# 60 atrophic gastritis 60 voriconazole 60 heparin induced thrombocytopenia 60 tertile 60 neurologic outcomes 60 severe rotavirus gastroenteritis 60 aldosterone antagonists 60 lopinavir r 60 β blocker 60 abacavir lamivudine 60 Skin rashes 60 symptomatic DVT 60 TRAIL R1 60 chlorambucil 60 HOMA IR 60 metabolic alkalosis 60 T2DM 60 multivariable analysis 60 testicular tumors 60 fasting insulin 60 hepatic impairment 60 VTEs 60 Juvenile Idiopathic Arthritis 60 interferon alfa 2b 60 electrolyte abnormalities 60 hepatic failure 60 tirofiban 60 bacteraemia 60 posaconazole 60 serum urate 60 S. aureus isolates 60 adenomatous polyps 60 hydronephrosis 60 R# #mg BID 60 revascularizations 60 VAPRISOL 60 FDG uptake 60 binary restenosis 60 #mg BID [002] 60 X ULN 60 hypersensitivity reactions 60 Relapsing remitting MS 60 hyperactivity impulsivity 60 hypersomnia 60 ACR# ACR# 60 nighttime awakenings 60 nevirapine Viramune 60 NYHA Class II 60 dysmenorrhoea 60 confidence interval CI 60 CANCIDAS 60 rebleeding 60 complement inhibitor eculizumab 60 nonmetastatic 59 Non inferiority 59 homozygous familial hypercholesterolemia 59 transferrin saturation 59 GH deficiency 59 IgA deficiency 59 invasive ductal 59 risperidone Risperdal 59 liver transaminases 59 5-FU/LV 59 CK # plasma concentrations 59 CI -#.# 59 akinesia 59 primary aldosteronism 59 elevated serum creatinine 59 % Confidence Interval 59 beta blocker therapy 59 colorectal liver metastases 59 ZYVOX 59 postintervention 59 ug dose 59 CMV infection 59 valsartan amlodipine 59 dopaminergic therapy 59 Vertebral fractures 59 dysthymia 59 atherothrombotic disease 59 mcg Albuferon 59 stent thromboses 59 μmol L 59 neoplasm 59 systolic dysfunction 59 BYSTOLIC 59 apolipoprotein B 59 idiopathic PAH 59 hypoperfusion 59 histologically confirmed 59 pulmonary infiltrates 59 primary hypercholesterolemia 59 serum aminotransferase levels 59 abdominal pain flatulence 59 pulmonary exacerbation 59 Aortic stenosis 59 bezafibrate 59 coronary calcification 59 Thyroid nodules 59 lipid abnormalities 59 vertebral fracture 59 serum concentrations 59 genitourinary GU 59 pimecrolimus cream 59 neurological manifestations 59 QTc 59 ARCALYST ® 59 baseline A1C 59 intima media thickness 59 tumor regressions 59 subsyndromal 59 nonvertebral 59 hyperhomocysteinemia 59 nerve toxicity neurotoxicity 59 gastroduodenal 59 nasopharyngitis upper 59 serum HBV DNA 59 interferon ribavirin 59 histological subtype 59 left ventricular systolic 59 post thrombotic syndrome 59 gastrointestinal toxicity 59 chronic GVHD 59 neutropenic sepsis 59 INVEGA ® 59 insomnia somnolence 59 Venous thromboembolism 59 non splenectomized 59 atopic eczema 59 mycophenolate mofetil 59 oral FTY# 59 aminotransferase elevations greater 59 stenoses 59 MYCAMINE 59 intra abdominal abscess 59 mg Proellex 59 intraoperative complications 59 FOLFOX4 59 Chronic HCV 59 #mg/day [002] 59 affective psychoses 59 timepoint 59 progressive PsA 59 thyrotropin levels 59 Heavy menstrual bleeding 59 Hurthle cell 59 spontaneous bowel movements 59 hypertension hypercholesterolemia 59 certolizumab pegol 59 mEq L 59 cIAI 59 COPAXONE R 59 p = #.# [002] 59 rheumatoid factor 59 Retreatment 59 HMG CoA reductase inhibitors 59 cerebrovascular accident 59 Osteoarthritis OA 59 hypopituitarism 59 corrected QT interval 59 contrast induced nephropathy 59 somnolence dizziness 59 serum phosphorous 59 Castration Resistant Prostate Cancer 59 Severe hypoglycemia 59 Kidney toxicity nephrotoxicity 59 HCV genotype 59 IIIa inhibitor 59 gastrointestinal adverse reactions 59 PSADT 59 renal dysfunction 59 creatinine clearance 59 stage IIIB 59 Folfox 59 paclitaxel eluting stents 59 Torsades de Pointes 59 paroxetine Paxil 59 follicular lymphoma FL 59 ribavirin therapy 59 antiarrhythmic drugs 59 venous thromboembolic events 59 postoperative morbidity 59 Score TOS 59 adrenal suppression 59 included exfoliative dermatitis 59 metastatic GIST 59 dosing cohorts 59 hepatotoxicity 59 ropivacaine 59 Peg IFN 59 polyp recurrence 59 Pharmacokinetic parameters 59 Hypomagnesemia occurred 59 leukemia AML 59 abacavir Ziagen 59 atazanavir ritonavir 59 multivariate adjustment 59 ALT AST 59 patients evaluable 59 MMSE score 59 severe renal impairment 59 invasive candidiasis 59 -#.# mg dL [002] 59 serum uric acid 59 partial remissions 59 neurodevelopmental impairment 59 severe mitral regurgitation 59 pyelonephritis 59 preoperative PSA 59 antiemetics 59 HRQL 59 events thrombocytopenia neutropenia 59 underwent resection 59 nonhematologic adverse reactions 59 HCV RESPOND 2 59 flutamide 59 abnormal lipid 59 urolithiasis 59 antiepileptics 59 venlafaxine Effexor 59 idarubicin 59 gross hematuria 59 neutropenic patients 59 VFEND 59 tumor necrosis 59 juvenile myoclonic epilepsy 59 dysglycemia 59 immunocompetent 59 TT genotype 59 methotrexate monotherapy 59 hepatocellular carcinomas 59 active comparator 59 elevated IOP 59 endometrial carcinoma 59 POAG 59 diastolic hypertension 59 resuscitated cardiac arrest 59 vaccinees 59 SSRI SNRI 59 p = #.# [003] 59 Lactic acidosis 59 complete remissions 59 bronchial hyperresponsiveness 59 postmenopausal osteoporotic women 59 serum PTH 59 sUA 59 univariate 59 glycated hemoglobin HbA1c 59 GSK# [001] 59 lispro 59 MIRAPEX ER 59 HGPIN 59 PsA 59 NYHA Class III 59 statistically significant p 59 antihypertensive medications 59 DMARD therapy 59 failure ADHF 59 octreotide LAR 59 FOLFIRI 59 coinfected patients 59 covariate 59 LPV r 59 serum phosphate 58 ß blockers 58 mg administered orally 58 Severe cutaneous 58 HBeAg 58 perioperative complications 58 telaprevir dosing 58 #mmHg [001] 58 hypoxemia 58 anaphylactoid reactions 58 neoplasms 58 PCWP 58 lowest tertile 58 inactivated poliovirus vaccine 58 congenital malformations 58 antiretroviral naïve 58 calculi 58 ejection fractions 58 nonsignificant 58 valacyclovir 58 potassium sparing diuretics 58 liver enzymes ALT 58 angioedema 58 lumbar spine BMD 58 Chronic ITP 58 nonfatal myocardial infarction 58 Zometa hazard 58 upper gastrointestinal bleeding 58 carotid IMT 58 thromboses 58 idraparinux 58 pulmonary dysfunction 58 ARCOXIA 58 CTEPH 58 prostate cancer CaP 58 adriamycin 58 hormone receptor negative 58 riociguat 58 systemic lupus erythematosus SLE 58 KRAS mutations occur 58 hepatic cirrhosis 58 asthma exacerbations 58 curative resection 58 peginterferon alfa 2b 58 genital ulcers 58 pegylated interferon alfa 2b 58 eosinophilia 58 UPDRS motor 58 rFVIIa 58 androgen deprivation 58 tacrolimus ointment 58 variceal bleeding 58 GnRH agonist 58 urine albumin 58 #OHD 58 REYATAZ r 58 IFN beta 58 delayed CINV 58 CYPHER Stent 58 papillary renal cell carcinoma 58 BRCA1 mutation carriers 58 Nilotinib 58 hemodialysis patients 58 systolic hypertension 58 thrombotic events 58 clinically meaningful improvements 58 plus GP IIb 58 HDRS 58 baseline FEV 58 postoperative mortality 58 clodronate 58 lumbar spine bone 58 QTc intervals 58 habitual snoring 58 pravastatin therapy 58 Immune responses 58 XIENCE V PROMUS Stent 58 hypopneas 58 coinfected 58 endoscopic remission 58 etiologies 58 leukocyte count 58 isolated systolic hypertension 58 zolmitriptan 58 myeloproliferative diseases 58 SGOT 58 femoral shaft fracture 58 fasting plasma glucose FPG 58 paroxysmal AF 58 Kaplan Meier estimates 58 chlorthalidone 58 acute coronary syndromes ACS 58 nonfatal myocardial infarction MI 58 BENICAR 58 exacerbations 58 ng dL 58 postoperative complications 58 glycosylated hemoglobin HbA1c 58 transfusion syndrome 58 refractory NSCLC 58 Postoperative 58 left ventricular ejection 58 acetabular dysplasia 58 HER2 overexpression 58 systemic corticosteroid 58 squamous 58 EURIDIS 58 lactic acidosis 58 achieved CCyR 58 Montgomery Asberg Depression 58 Haptoglobin 58 de novo AML 58 angioneurotic edema 58 pulmonary toxicity 58 MULTAQ 58 visceral metastases 58 HIV uninfected 58 Secondary endpoints include 58 YMRS 58 reoperations 58 Gliomas